Exelixis
EXEL
#1694
Rank
โ‚น1.072 T
Marketcap
โ‚น3,985
Share price
-0.02%
Change (1 day)
30.57%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Cash on Hand

Cash on Hand as of September 2025 : โ‚น88.80 Billion

According to Exelixis's latest financial reports the company has โ‚น88.80 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Exelixis - Cash on Hand chart (from 2000 to 2025)

Cash on Hand by year

Year Cash on Hand Change
2024-12-31โ‚น95.33 B15.06%
2023-12-31โ‚น82.85 B-23.48%
2022-12-31โ‚น108.27 B-0.84%
2021-12-31โ‚น109.19 B23.75%
2020-12-31โ‚น88.23 B45.19%
2019-12-31โ‚น60.77 B25.36%
2018-12-31โ‚น48.47 B95.8%
2017-12-31โ‚น24.75 B-13.21%
2016-12-31โ‚น28.52 B156.96%
2015-12-31โ‚น11.10 B21.41%
2014-12-31โ‚น9.14 B-38.95%
2013-12-31โ‚น14.97 B-33.51%
2012-12-31โ‚น22.52 B119.22%
2011-12-31โ‚น10.27 B40.99%
2010-12-31โ‚น7.28 B-22.65%
2009-12-31โ‚น9.42 B-25.29%
2008-12-31โ‚น12.61 B18.35%
2007-12-31โ‚น10.65 B34.51%
2006-12-31โ‚น7.92 B18.45%
2005-12-31โ‚น6.68 B-0.48%
2004-12-31โ‚น6.72 B-37.74%
2003-12-31โ‚น10.79 B1.4%
2002-12-31โ‚น10.64 B-3.11%
2001-12-31โ‚น10.98 B109.15%
2000-12-31โ‚น5.25 B1651.22%
1999-12-31โ‚น0.29 B

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
GlaxoSmithKline
GSK
โ‚น399.26 B 349.59%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
โ‚น938.96 B 957.31%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น1.636 T 1,742.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น1.482 T 1,569.34%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น848.50 B 855.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
โ‚น1.667 T 1,777.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น1.346 T 1,415.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
โ‚น0.81 B-99.08%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
โ‚น6.95 B-92.17%๐Ÿ‡บ๐Ÿ‡ธ USA